Oxford BioTherapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7543
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oxford BioTherapeutics Ltd (OBT) is a clinical stage oncology company that develops antibody drug conjugates for the treatment of variety of cancers. The company’s product pipelines currently includes T-cell based IO therapies including check point modulators; NK cell based IO therapies such as antibody dependent cell mediated toxicity (ADCCs); and Antibody drug conjugates (ADCs). Its therapeutic antibodies targets checkpoints restore anti-tumour immune function allowing the immune system to recognise and kill cancer cells. The company works in collaboration with companies for the development of component technologies to develop innovative ADCs. It operates through its offices in the UK and Switzerland. Oxford BioTherapeutics is headquartered in Abingdon, the UK.

Oxford BioTherapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Calculus Capital Invests USD2.6 Million in Oxford BioTherapeutics 11
Partnerships 12
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 12
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 13
Invenra Enters into Agreement with Oxford BioTherapeutics 14
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 15
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 16
Licensing Agreements 17
Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 17
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 18
Oxford BioTherapeutics Ltd – Key Competitors 19
Oxford BioTherapeutics Ltd – Key Employees 20
Oxford BioTherapeutics Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Corporate Communications 22
Jun 13, 2017: Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director 22
Feb 09, 2017: Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans 23
Product News 24
09/28/2017: Menarini Ricerche Attended the Brainstorming Meeting on CD38 and CD157 which was Held on September 21st-23rd 2017 at San Benedetto Po and Mantova (Italy) 24
03/01/2018: Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi M.D., Ph.D. 25
Clinical Trials 26
Sep 12, 2017: Oncology Research: New Opportunities for Menarini and OBT 26
Jun 21, 2017: Menarini Ricerche to Present the Most Recent Data About the Pre-Clinical Development of its Novel ABC Men1309/Obt076 at the 29th Pezcoller Symposium 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford BioTherapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Calculus Capital Invests USD2.6 Million in Oxford BioTherapeutics 11
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 12
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 13
Invenra Enters into Agreement with Oxford BioTherapeutics 14
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 15
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 16
Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 17
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 18
Oxford BioTherapeutics Ltd, Key Competitors 19
Oxford BioTherapeutics Ltd, Key Employees 20
Oxford BioTherapeutics Ltd, Subsidiaries 21

List of Figures
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Oxford BioTherapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Micromem Technologies Inc (MRM):企業の財務・戦略的SWOT分析
    Summary Micromem Technologies Inc (Micromem) operates as a technology company that develops and markets magnetic sensor products. The company designs and develops sensors specific to industrial requirements. It offers solutions such as nanoparticle detection solutions, structural integrity sensors, …
  • Claverack Rural Electric Cooperative Inc:企業の戦略的SWOT分析
    Claverack Rural Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • AstraZeneca AB-製薬・医療分野:企業M&A・提携分析
    Summary AstraZeneca AB (AstraZeneca), a subsidiary of AstraZeneca Plc is a healthcare products provider that research and development of medicinal products. The company offers research and produces drug products in heart and cardiovascular, infection, cancer, metabolic diseases, respiratory, stomach …
  • Nestle Health Science SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Nestle Health Science SA (Nestle Health), a subsidiary of Nestle SA, is a health science company that manufactures nutritional and medicinal products derived from botanical plants. The company provides nutritional therapies for chronic conditions related to gastrointestinal diseases, aging p …
  • Banco Cooperativo Espanol S.A.:企業の戦略・SWOT・財務分析
    Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Apache Corporation:企業の戦略・SWOT・財務分析
    Apache Corporation - Strategy, SWOT and Corporate Finance Report Summary Apache Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • WellSky Corp:企業の戦略的SWOT分析
    WellSky Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Hitachi Medical Systems America Inc-医療機器分野:企業M&A・提携分析
    Summary Hitachi Medical Systems America Inc (Hitachi Medical), a subsidiary of Hitachi Healthcare Manufacturing Ltd is a provider of diagnostic imaging equipment. The company offers MRI, CT, ultrasound, optical topography and x-ray equipment. Its services comprise construction assistance, rigging as …
  • Phoenix Beverages Limited:戦略・SWOT・企業財務分析
    Phoenix Beverages Limited - Strategy, SWOT and Corporate Finance Report Summary Phoenix Beverages Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ICU Medical Inc (ICUI):医療機器:M&Aディール及び事業提携情報
    Summary ICU Medical Inc (ICU Medical) is a medical device company which develops, manufactures, distributes and sells devices used for infusion therapy, cancer diagnosis and treatment and critical care applications. The company’s major products include needle free vascular access devices, closed sys …
  • Odebrecht SA:企業の戦略的SWOT分析
    Odebrecht SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • AB SKF (SKF B):企業の財務・戦略的SWOT分析
    AB SKF (SKF B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • BELLUS Health Inc (BLU)-製薬・医療分野:企業M&A・提携分析
    Summary BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second ind …
  • SAES Getters SpA (SG):企業の財務・戦略的SWOT分析
    SAES Getters SpA (SG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • EDF Energy Holdings Ltd:企業の発電所・SWOT分析2018
    EDF Energy Holdings Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • EndoGastric Solutions Inc-医療機器分野:企業M&A・提携分析
    Summary EndoGastric Solutions Inc (EGS), formerly EsophyX, Inc. is a medical equipment company that manufactures and markets gastroenterology and surgical products. The company’s products include esophy-x device and serosa-fuse fasteners. Its esophy-x device is used in reconstructing the gastroesoph …
  • Simplex Infrastructures Ltd:企業の戦略・SWOT・財務分析
    Simplex Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report Summary Simplex Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cesca Therapeutics Inc (KOOL)-医療機器分野:企業M&A・提携分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • UMN Pharma Inc (4585):企業の財務・戦略的SWOT分析
    Summary UMN Pharma Inc (UMN Pharma), a subsidiary of Shionogi Inc, is a biopharmaceutical company that manufactures therapeutic for muscular dystrophy, diabetes and influenza. The company’s pipeline products include UMN-101 for the treatment of Recombinant seasonal influenza vaccine; UMN-102 for rec …
  • Chong Kun Dang Pharmaceutical Corp (185750):企業の財務・戦略的SWOT分析
    Chong Kun Dang Pharmaceutical Corp (185750) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆